Crystal form of ozanimod hydrochloride and processes for preparation therefor
US10882830B2 · kind B2 · utility
1Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 14, 2017 |
| Grant date | Jan 5, 2021 |
| Priority date | — |
| Expiry date | Sep 14, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.